JPH10147575A - Hydroquinone derivative and its medical application - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a new compound useful for treating allergic diseases, especially diseases associated with allergy type-IV reaction, e.g. skin diseases such as atopic dermatitis, contact dermatitis and psoriasis. SOLUTION: A compound of the formula [R<1> is a (substituted) phenyl; R<2> to R<8> are each H or a 1-4C alkyl; P is OH; Q is OH, a 1-4C alkoxy, etc.; R is OH, a 1-4C alkoxy, etc.; when one of Q and R is oxo, the other is also oxo; X is a single bond, NR<10> (NR<10> is H or a 1-4C alkyl), etc.; Y is methylene or carbonyl; dotted lines mean that the ring has largest possible number of double bonds], e.g. 6-amino-5-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide)-3- methyl-l-phenyl-2,4(1H,3H)-pyrimidinedione. A compound of the formula can be obtained e.g. by reacting 5,6-diamino-3-methyl-1-phenyl-2,4(1H,3H)- pyrimidinedione with 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid and 4-(dimethylamino)pyridine.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

[0001] The present invention relates to a novel hydroquinone derivative useful for treating various allergic diseases and its pharmaceutical use, and more particularly to a therapeutic agent for allergic diseases containing the compound as an active ingredient.

[0002]

2. Description of the Related Art Allergic reactions causing allergic diseases are mainly classified into type I to type IV. Atopic dermatitis, contact dermatitis, chronic bronchial asthma, psoriasis, graft-versus-host disease, etc. It is said that type IV involvement is large.
The efficacy of antihistamines and chemical mediator release inhibitors for these diseases is limited, and treatment with steroids is being performed. Furthermore, immunosuppressants such as cyclosporine and tacrolimus are effective in suppressing rejection after organ transplantation and in treating graft-versus-host disease, and the application of these drugs to the treatment of dermatitis is expanding (Lancet, 339). , 1120
(1992); J. Invest. Dermatol., 98 , 851 (1992), etc.).
However, steroids have side effects such as infectious diseases, adrenal atrophy, osteoporosis, diabetes, and impaired growth in children, and the immunosuppressive agents cyclosporine and tacrolimus also have side effects derived from their immunosuppressive effects, such as There is concern about the development of diabetes and the like.

The present applicant has previously proposed a uracil derivative which suppresses type IV allergic reaction (Japanese Patent Laid-Open No. Hei 8-1091).
No. 71, EP-A1-700908), there is still a need for the development of a more effective and safe therapeutic agent for allergic diseases, particularly therapeutic agents for diseases associated with type IV allergic reaction.

[0004]

DISCLOSURE OF THE INVENTION The present invention has been made to solve the above-mentioned problems, and an object of the present invention is to provide a method useful for the treatment of various allergic diseases, particularly those involving a type IV allergic reaction. An object of the present invention is to provide a novel compound and a remedy for allergic diseases containing the same as an active ingredient.

[0005]

Means for Solving the Problems The present inventors have conducted intensive studies to develop therapeutics for various allergic diseases, particularly those involving type IV allergic reactions, and as a result, 2,4 (1H,
The present inventors have found that a hydroquinone derivative having a 3H) -pyrimidinedione ring markedly suppresses a type IV allergic reaction, thereby completing the present invention. That is, the present invention provides a compound represented by the general formula (I):

[0006]

Embedded image (Wherein, R ¹ represents a phenyl group, and the phenyl group is a halogen atom, an alkyl group having 1 to 4 carbon atoms, or a 1 to 1 carbon atom.
R ² may represent a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, and R ³ and R ⁴
Independently represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, R ⁵ represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, and R ⁶ , R ⁷ and R ⁸ independently represent a hydrogen atom Or represents an alkyl group having 1 to 4 carbon atoms; P represents a hydroxyl group;
Is a hydroxyl group, an alkoxy group having 1 to 4 carbon atoms,
Represents an acyloxy group or an oxo group of 18, wherein P and Q are
R may represent a hydroxyl group, an alkoxy group having 1 to 4 carbon atoms, an acyloxy group or an oxo group having 1 to 18 carbon atoms, provided that one of the Q and R is When an oxo group, the other is also an oxo group, and X represents a single bond, a —NR ¹⁰ — group or a —CH ₂ —NR ¹⁰ — group,
Here, R ¹⁰ represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, Y represents a methylene group or a carbonyl group,
The dotted line attached to the 6-membered ring indicates that the ring has the most double bonds. ) Or a pharmacologically acceptable salt thereof, and a pharmaceutical composition containing the compound as an active ingredient, particularly a therapeutic drug for allergic diseases.

[0007]

BEST MODE FOR CARRYING OUT THE INVENTION The hydroquinone derivative of the present invention and a pharmaceutically acceptable salt thereof will be specifically described below.
In the hydroquinone derivative of the present invention, as shown in the general formula (I), the carbon atom to which R ⁵ and P are bonded is an asymmetric carbon atom, and two types of optical isomers exist depending on the configuration on the carbon atom. However, the present invention includes any of them. In addition, the hydroquinone derivative of the present invention has the general formula (II):

[0008]

Embedded image (Wherein P, Q, R, R ⁵ , R ⁶ , R ⁷ and R ⁸ are the same groups as P, Q, R, R ⁵ , R ⁶ , R ⁷ and R ⁸ in the general formula (I), respectively) Wherein the dotted line attached to the six-membered ring indicates that the ring has the most double bonds.) The hydroquinone ring or hydroquinone-related structure represented by the general formula (II) According to the selection of P, Q and R to be included, the following three types of structures are obtained. That is, the general formula (III) in which P and Q together form an ether bond:

[0009]

Embedded image (Wherein, R ⁵ , R ⁶ , R ⁷ and R ⁸ each represent the same group as R ⁵ , R ⁶ , R ⁷ and R ^{8 in} formula (I);
¹² represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms or an acyl group having 1 to 18 carbon atoms. ), Chroman structure,
P is a hydroxyl group, Q and R are a hydroxyl group and a carbon number 1 respectively.
General formula (IV) which is an alkoxy group having 1 to 4 or an acyloxy group having 1 to 18 carbon atoms:

[0010]

Embedded image (Wherein, R ⁵ , R ⁶ , R ⁷ and R ⁸ each represent the same group as R ⁵ , R ⁶ , R ⁷ and R ^{8 in} formula (I);
¹¹ and R ¹² each represent a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, or an acyl group having 1 to 18 carbon atoms. A) a hydroquinone structure which is a hydrated form of the chroman structure (III), wherein P is a hydroxyl group, and Q and R are both oxo groups;

[0011]

Embedded image (In the formula, R ⁵ , R ⁶ , R ⁷ and R ⁸ each represent the same group as R ⁵ , R ⁶ , R ⁷ and R ^{8 in} formula (I).)
And three types of quinone structures which are oxidized forms of the hydroquinone structure (IV). In general, these three structures are closely related to each other and are capable of reversible interconversion (see, for example, J. Org. Chem., 4
6 , 2445 (1981), etc.). For example, for conversion from a chroman structure to a quinone structure, α-tocopherol (R ⁵ = R ⁶ = R
⁷ = R ⁸ = CH ₃ , R ¹² = H) has the general formula (V)
It is also known to produce α-tocopherol quinone having as a partial structure (for example, J. Biol. Chem., 23
8, 2912 (1963)).

R ² and R of the compound represented by formula (I)
³ , R ⁴ , R ⁵ , R ⁶ , R ⁷ , R ⁸ and R ^{10 each represent} a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, that is, a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, a sec. -
Examples thereof include a butyl group, a tert-butyl group and an isobutyl group, and a hydrogen atom or a methyl group is preferred.

The compound of the general formula (I) constituting the compound of the present invention
R ^5, R ^6, R ⁷ substituting on the backbone of I), and used to select a hydrogen atom or a methyl group R ^8, specifically, the chroman structure of the general formula (III), 2-methyl - 6-hydroxy-2-chromanyl group, 2,8-dimethyl-6-hydroxy-2-
Chromanyl group, 2,5,8-trimethyl-6-hydroxy-2-chromanyl group, 2,7,8-trimethyl-6-hydroxy-2-chromanyl group, 2,5,7,8-tetramethyl-6- In the hydroquinone structure of the general formula (IV) such as a hydroxy-2-chromanyl group,
3- (2,5-dihydroxyphenyl) -1-hydroxy-1-methylpropyl group, 3- (2,5-dihydroxy-3-methylphenyl) -1-hydroxy-1-methylpropyl group, 3- (2 , 5-dihydroxy-3,6-dimethylphenyl) -1-hydroxy-1-methylpropyl group, 3- (2,5-dihydroxy-3,4-dimethylphenyl) -1-hydroxy-1-methylpropyl group, 3- (2,5
-In the quinone structure of the general formula (V) such as dihydroxy-3,4,6-trimethylphenyl) -1-hydroxy-1-methylpropyl group, 3- (1,4-benzoquinone-2-yl) -1- Hydroxy
-1-methylpropyl group, 1-hydroxy-1-methyl-3- (6-
Methyl-1,4-benzoquinone-2-yl) propyl group, 3-
(3,6-dimethyl-1,4-benzoquinone-2-yl) -1-hydroxy-1-methylpropyl group, 3- (5,6-dimethyl-1,4-benzoquinone-2-yl) -1- Hydroxy-1-methylpropyl group, 1-hydroxy-1-methyl-3- (3,5,6-trimethyl-1,4
-Benzoquinone-2-yl) propyl group and the like, particularly 2,5,7,8-tetramethyl-6-hydroxy-2-chromanyl group, 3- (2,5-dihydroxy-3,4,6 -Trimethylphenyl) -1-hydroxy-1-methylpropyl group, 1-hydroxy
-1-methyl-3- (3,5,6-trimethyl-1,4-benzoquinone-2
-Yl) propyl group is a preferred partial skeleton.

The hydrogen atom of the phenolic hydroxyl group on the benzene ring of the chroman structure of the general formula (III) or the hydroquinone structure of the general formula (IV) is an alkyl group having 1 to 4 carbon atoms or a hydrogen atom having 1 to 18 carbon atoms. May be substituted with an acyl group. That is, in the general formula (III), R ¹² is a hydrogen atom, an alkyl group having 1 to 4 carbon atoms or an acyl group having 1 to 18 carbon atoms, particularly preferably a hydrogen atom or an acyl group. In the above, R ¹¹ and R ¹² are each independently a hydrogen atom, an alkyl group having 1 to 4 carbon atoms or an acyl group having 1 to 18 carbon atoms, and particularly preferably a hydrogen atom or an acyl group. R
When using a suitable hydrogen atom or an acyl group as ¹¹ and R ^12, OR ¹¹ group and OR ¹² groups are a hydroxyl group protected by a hydroxyl group or an acyl group. Examples of the acyl group include alkanoyl such as formyl group, acetyl group, propionyl group, butanoyl group, pentanoyl group, hexanoyl group, octanoyl group, decanoyl group, dodecanoyl group, tetradecanoyl group, hexadecanoyl group, and octadecanoyl group. And acyl groups containing an aromatic ring such as a benzoyl group, anisoyl group (methoxybenzoyl group), a phenylacetyl group and a phenylpropionyl group.

The compound of the formula (I) 2,4 (1H,
3H) -R ¹ on the 1-position of the pyrimidinedione ring represents a phenyl group substituted with a halogen atom, an alkyl group having 1 to 4 carbon atoms or an alkoxy group having 1 to 4 carbon atoms, or an unsubstituted phenyl group. . Here, the halogen atom is fluorine, chlorine, bromine, or iodine, and preferably, any one of fluorine, chlorine, and bromine is used. The alkyl group having 1 to 4 carbon atoms is a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, a sec-butyl group, a tert-butyl group, a linear or branched alkyl group of an isobutyl group,
The alkoxy group having 1 to 4 carbon atoms is an alkyloxy group composed of the above alkyl group.

Specific examples of the substituted phenyl group are shown below.
As a phenyl group substituted by a halogen atom such as fluorine, chlorine, and bromine, a 2-fluorophenyl group, a 3-fluorophenyl group, a 4-fluorophenyl group, a 2-chlorophenyl group, a 3-chlorophenyl group, a 4-chlorophenyl group, 2-bromophenyl group, 3-bromophenyl group, 4-bromophenyl group, 2,3-difluorophenyl group, 2,4-difluorophenyl group, 2,5-difluorophenyl group, 2,6-difluorophenyl group, 3,4-difluorophenyl group, 3,5-difluorophenyl group, 2,3-dichlorophenyl group, 2,4-dichlorophenyl group, 2,5-dichlorophenyl group, 2,6-dichlorophenyl group, 3,4-dichlorophenyl group , 3,5-dichlorophenyl group, 2,4-dibromophenyl group, 2,5-dibromophenyl group, 2,6-dibromophenyl group, 2-chloro-4-fluorophenyl group, 3-chloro-4-fluorophenyl Group, 4-black
-2-fluorophenyl group, 4-bromo-2-chlorophenyl group, 2,3,4-trifluorophenyl group, 2,3,6-trifluorophenyl group, 2,4,5-trifluorophenyl group, 2 , 4,6-
Trifluorophenyl group, 2,3,4-trichlorophenyl group, 2,4,5-trichlorophenyl group, 2,4,6-trichlorophenyl group, 3,4,5-trichlorophenyl group, and the like. .

The phenyl group substituted by an alkyl group having 1 to 4 carbon atoms includes 2-methylphenyl group, 3-methylphenyl group, 4-methylphenyl group, 2-ethylphenyl group and 3-ethylphenyl group. , 4-ethylphenyl, 2-propylphenyl, 4-propylphenyl, 2-tert-butylphenyl, 4-butylphenyl, 4-tert-butylphenyl, 4-sec-butylphenyl, 2 , 3-dimethylphenyl group, 2,4-dimethylphenyl group, 2,5-dimethylphenyl group, 2,6-dimethylphenyl group, 3,4-dimethylphenyl group, 3,5-dimethylphenyl group, 2,6 -Diethylphenyl group, 2,5-di-tert-butylphenyl group, 3,5-di-tert-butylphenyl group, 2,4,6-trimethylphenyl group and the like. Similarly, as a phenyl group substituted by an alkoxy group having 1 to 4 carbon atoms, 2-methoxyphenyl group, 3-methoxyphenyl group, 4-methoxyphenyl group, 2-methoxyphenyl group,
An ethoxyphenyl group, a 3-ethoxyphenyl group, a 4-ethoxyphenyl group and the like can be exemplified.

In addition, phenyl groups having a plurality of types of substituents include 2-fluoro-4-methylphenyl group, 2-fluoro
-5-methylphenyl group, 3-fluoro-2-methylphenyl group, 3-fluoro-4-methylphenyl group, 4-fluoro-2-
Methylphenyl group, 5-fluoro-2-methylphenyl group,
2-chloro-4-methylphenyl group, 2-chloro-5-methylphenyl group, 2-chloro-6-methylphenyl group, 3-chloro-2
-Methylphenyl group, 3-chloro-4-methylphenyl group,
2-bromo-4-methylphenyl group, 3-bromo-4-methylphenyl group, 4-bromo-2-methylphenyl group, 4-bromo-3
-Methylphenyl, 3-fluoro-2-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 3-chloro-4-
Methoxyphenyl group, 5-chloro-2-methoxyphenyl group, 2-chloro-5-methoxyphenyl group, 2-methoxy-5-
Methylphenyl group, 2-methoxy-6-methylphenyl group, 4
Examples thereof include -methoxy-2-methylphenyl group and 5-methoxy-2-methylphenyl group.

The compound represented by the general formula (I)
R ² on the 3rd position of the 4 (1H, 3H) -pyrimidinedione ring is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, and it is preferable to select a hydrogen atom or a methyl group. Similarly, 2,4 (1H, Three
In the NR ³ R ⁴ group on the 6-position of the (H) -pyrimidinedione ring, R ³ and R ⁴ are a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, and it is preferable to select a hydrogen atom or a methyl group.

Among the compounds represented by the general formula (I), those having a chroman structure represented by the general formula (III) are 2,4 (1H, 3
H) -has a basic structure in which a pyrimidinedione ring and a chroman ring are connected by -XY-. For example, X is -NR ¹⁰ - group, Y
Is a carbonyl group, 5- (chroman-2-carboxamide) -2,4 (1H, 3H) -pyrimidinedione, 5- (N-methylchroman-2-carboxamide) -2,4 (1H, 3H)- Pyrimidinedione, 5- (N-ethylchroman-2-carboxamide) -2,
4 (1H, 3H) -pyrimidinedione, 5- (N-propylchroman-2-carboxamide) -2,4 (1H, 3H) -pyrimidinedione, 5- (N-butylchroman-2-carboxamide) -2, 4 (1
H, 3H) - pyrimidinedione, X is -NR ¹⁰ - group, Y is a methylene group, 5- [N- (2- chroma sulfonyl methyl) amino] -
2,4 (1H, 3H) -pyrimidinedione, 5- [N- (2-chromanylmethyl) -N-methylamino] -2,4 (1H, 3H) -pyrimidinedione, 5- [N- (2 -Chromanylmethyl) -N-ethylamino] -2,
4 (1H, 3H) -pyrimidinedione, 5- [N- (2-chromanylmethyl) -N-propylamino] -2,4 (1H, 3H) -pyrimidinedione, 5- [N-butyl-N- (2-chromanylmethyl) amino] -2,4 (1H, 3H) -pyrimidinedione, X is a single bond, Y
Is a methylene group or a carbonyl group, 5- (2-chromanylmethyl) -2,4 (1H, 3H) -pyrimidinedione, 5- (2-chromancarbonyl) -2,4 (1H, 3H) -pyrimidine Zeon,
X is -CH ₂ -NR ¹⁰ - group, Y is a methylene group, 5-
[N- (2-chromanylmethyl) aminomethyl] -2,4 (1H, 3H)
-Pyrimidinedione, 5- [N- (2-chromanylmethyl) -N-methylaminomethyl] -2,4 (1H, 3H) -pyrimidinedione,
5- [N- (2-chromanylmethyl) -N-ethylaminomethyl] -2,
4 (1H, 3H) -pyrimidinedione, 5- [N- (2-chromanylmethyl) -N-propylaminomethyl] -2,4 (1H, 3H) -pyrimidinedione, 5- [N-butyl-N -(2-Chromanylmethyl)
Aminomethyl] -2,4 (1H, 3H) -pyrimidinedione, where X is
5- (chroman-2-carboxamidomethyl) -2,4 (1H, 3H) -pyrimidinedione, 5- (N-methylchroman-2-carboxamide, wherein -CH ₂ -NR ¹⁰ -group and Y is a carbonyl group Methyl) -2,4 (1H, 3H) -pyrimidinedione, 5- (N-ethylchroman-2-carboxamidomethyl) -2,4 (1H, 3H)-
Pyrimidinedione, 5- (N-propylchroman-2-carboxamidomethyl) -2,4 (1H, 3H) -pyrimidinedione, 5-
(N-butylchroman-2-carboxamidomethyl) -2,4 (1
It has a basic structure such as (H, 3H) -pyrimidinedione. In these basic structures, the aforementioned R ¹ , R ² ,
Having NR ³ R ⁴ and 2,5,6,7,8 of the chroman ring
R ⁵ , R ⁶ , OR ¹² , R ⁷ , R ⁸
Having.

Among the compounds represented by the general formula (I), those having a hydroquinone structure of the general formula (IV) are obtained by replacing the 2-chromanyl group of the basic structure having a chroman ring with a 3-phenylpropyl group. Having a hydroxyl group and R ⁵ at the 1-position of the propyl group of the 3-phenylpropyl group;
OR ¹¹ groups, R ⁸ , R ⁷ , O
It has R ¹² and R ⁶ .

Among the compounds represented by the general formula (I), those having a quinone structure represented by the general formula (V) have a 2-chromanyl group having a basic structure having a chroman ring as 3- (1,4-benzoquinone-). 2- (yl) propyl group, the 3- (1,4-benzoquinone-2-yl) propyl group has a hydroxyl group and R ⁵ at the 1-position of the propyl group, 1,4-benzoquinone-2-yl)
The yl group has R ⁶ , R ⁷ , and R ⁸ at positions 3, 5, and 6, respectively.

In the above basic structure, a group which is substituted on the 2,4 (1H, 3H) -pyrimidinedione ring and the skeleton of the general formula (II) is
When each of the aforementioned preferable groups is selected, a hydroquinone derivative suitable in the present invention is obtained. Further, R ² , R ³ and R ⁴ on the 2,4 (1H, 3H) -pyrimidinedione ring of the compound represented by the general formula (I), and R ⁵ , R ⁶ , and R in the skeleton of the general formula (II) ^It is more preferable to select a hydrogen atom or a methyl group for each of ⁷ and R ⁸ and R ^{10 in} —XY—. In particular, the general formula (I
When all of R ⁵ , R ⁶ , R ⁷ and R ⁸ present in the skeleton of I) are methyl groups, a still more preferred compound is obtained.

As an example of such particularly preferred compounds, those having a chroman structure of the general formula (III) include 6-amino-5- (6-hydroxy-2,5,7,8-tetramethyl Chroman-2-carboxamide) -3-methyl-1-phenyl
-2,4 (1H, 3H) -pyrimidinedione, 6-amino-1- (4-fluorophenyl) -5- (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide)- 3-methyl-2,4 (1H, 3
H) -pyrimidinedione, 6-amino-1- (4-chlorophenyl)
-5- (6-hydroxy-2,5,7,8-tetramethylchroman-2-
(Carboxamido) -3-methyl-2,4 (1H, 3H) -pyrimidinedione, 6-amino-1- (2-chlorophenyl) -5- (6-hydroxy-2,5,7,8-tetramethylchroman- 2-carboxamido) -3-methyl-2,4 (1H, 3H) -pyrimidinedione, 6-amino-1- (3-chlorophenyl) -5- (6-hydroxy-2,5,7,8-
Tetramethylchroman-2-carboxamide) -3-methyl-
2,4 (1H, 3H) -pyrimidinedione, 6-amino-5- (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide) -3-methyl-1- (4-methyl (Phenyl) -2,4 (1H, 3H)-
Pyrimidinedione, 6-amino-5- (6-hydroxy-2,5,7,8
-Tetramethylchroman-2-carboxamide) -1- (4-methoxyphenyl) -3-methyl-2,4 (1H, 3H) -pyrimidinedione, 5- (6-hydroxy-2,5,7,8- Tetramethylchroman-2-carboxamide) -3-methyl-6-methylamino-1-
Phenyl-2,4 (1H, 3H) -pyrimidinedione, 6-dimethylamino-1- (4-fluorophenyl) -5- (6-hydroxy-2,
5,7,8-tetramethylchroman-2-carboxamide) -3-
Methyl-2,4 (1H, 3H) -pyrimidinedione, 5- (6-acetoxy-2,5,7,8-tetramethylchroman-2-carboxamide) -6-amino-3-methyl-1-phenyl- 2,4 (1H, 3H) -pyrimidinedione, 6-amino-5-[(6-hydroxy-2,5,7,8
-Tetramethyl-2-chromanylmethyl) amino] -3-methyl-1-phenyl-2,4 (1H, 3H) -pyrimidinedione, 6-amino-5- (6-hydroxy-2,5,7, 8-tetramethyl-2-chromanylmethyl) -3-methyl-1-phenyl-2,4 (1H, 3H) -pyrimidinedione, 6-amino-5- (6-hydroxy-2,5,7,8 -
(Tetramethyl-2-chromancarbonyl) -3-methyl-1-phenyl-2,4 (1H, 3H) -pyrimidinedione, 6-amino-5-
[N- (6-hydroxy-2,5,7,8-tetramethyl-2-chromanylmethyl) aminomethyl] -3-methyl-1-phenyl-2,4
(1H, 3H) -pyrimidinedione, 6-amino-5- (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamidomethyl) -3-methyl-1-phenyl-2,4 ( 1H, 3H) -pyrimidinedione, 6-amino-3-methyl-5- (N-methyl-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamidomethyl) -1-phenyl-2 , 4 (1H, 3H) -pyrimidinedione;

Examples of the compound having a hydroquinone structure of the general formula (IV) include 6-amino-5- [4- (2,5-diacetoxy-3,
4,6-trimethylphenyl) -2-hydroxy-2-methylbutyramide] -3-methyl-1-phenyl-2,4 (1H, 3H) -pyrimidinedione, 6-amino-5- [4- (2 , 5-diacetoxy-3,
4,6-trimethylphenyl) -2-hydroxy-2-methylbutyramide] -1- (4-fluorophenyl) -3-methyl-2,4
(1H, 3H) -pyrimidinedione, 6-amino-1- (4-chlorophenyl) -5- [4- (2,5-diacetoxy-3,4,6-trimethylphenyl) -2-hydroxy-2-methyl Butyramido] -3-methyl-2,4 (1H, 3H) -pyrimidinedione, 6-amino-1- (2-chlorophenyl) -5- [4- (2,5-diacetoxy-3,4,6- Trimethylphenyl) -2-hydroxy-2-methylbutyramide]-
3-methyl-2,4 (1H, 3H) -pyrimidinedione, 6-amino-1
-(3-chlorophenyl) -5- [4- (2,5-diacetoxy-3,4,6-
Trimethylphenyl) -2-hydroxy-2-methylbutyramide] -3-methyl-2,4 (1H, 3H) -pyrimidinedione, 6-amino-5- [4- (2,5-diacetoxy-3,4 , 6-Trimethylphenyl) -2-hydroxy-2-methylbutyramide] -3-methyl
-1- (4-methylphenyl) -2,4 (1H, 3H) -pyrimidinedione, 6-amino-5- [4- (2,5-diacetoxy-3,4,6-trimethylphenyl) -2- Hydroxy-2-methylbutyramide]-
1- (4-methoxyphenyl) -3-methyl-2,4 (1H, 3H) -pyrimidinedione, 5- [4- (2,5-diacetoxy-3,4,6-trimethylphenyl) -2-hydroxy -2-methylbutyramide]-
3-methyl-6-methylamino-1-phenyl-2,4 (1H, 3H)-
Pyrimidinedione, 5- [4- (2,5-diacetoxy-3,4,6-trimethylphenyl) -2-hydroxy-2-methylbutyramide] -6-dimethylamino-1- (4-fluorophenyl)- 3-methyl-2,4 (1H, 3H) -pyrimidinedione, 6-amino-5- [4-
(2,5-dihydroxy-3,4,6-trimethylphenyl) -2-hydroxy-2-methylbutyramide] -3-methyl-1-phenyl-2,4 (1H, 3H) -pyrimidinedione, 6- Amino-5-[[4-
(2,5-diacetoxy-3,4,6-trimethylphenyl) -2-hydroxy-2-methylbutyl] amino] -3-methyl-1-phenyl-2,4 (1H, 3H) -pyrimidinedione, 6- Amino-5- [4-
(2,5-diacetoxy-3,4,6-trimethylphenyl) -2-hydroxy-2-methylbutyl] -3-methyl-1-phenyl-2,4
(1H, 3H) -pyrimidinedione, 6-amino-5- [4- (2,5-diacetoxy-3,4,6-trimethylphenyl) -2-hydroxy
-2-methylbutyryl] -3-methyl-1-phenyl-2,4 (1H,
3H) -pyrimidinedione, 6-amino-5- [N- [4- (2,5-diacetoxy-3,4,6-trimethylphenyl) -2-hydroxy-2-
Methylbutyl] aminomethyl] -3-methyl-1-phenyl-
2,4 (1H, 3H) -pyrimidinedione, 6-amino-5- [4- (2,5-
Diacetoxy-3,4,6-trimethylphenyl) -2-hydroxy-2-methylbutylamidomethyl] -3-methyl-1-phenyl-2,4 (1H, 3H) -pyrimidinedione;

The compound having a quinone structure represented by the general formula (V) includes 6-amino-3-methyl-1-phenyl-5- [4- (3,5,6
-Trimethyl-1,4-benzoquinone-2-yl) -2-hydroxy-2-methylbutyramide] -2,4 (1H, 3H) -pyrimidinedione, 6-amino-1- (4-fluorophenyl)- 3-methyl-5
-[4- (3,5,6-trimethyl-1,4-benzoquinone-2-yl)-
2-Hydroxy-2-methylbutyramide] -2,4 (1H, 3H)-
Pyrimidinedione, 6-amino-1- (4-chlorophenyl) -3-
Methyl-5- [4- (3,5,6-trimethyl-1,4-benzoquinone-2
-Yl) -2-hydroxy-2-methylbutyramide] -2,4 (1
(H, 3H) -pyrimidinedione, 6-amino-1- (2-chlorophenyl) -3-methyl-5- [4- (3,5,6-trimethyl-1,4-benzoquinone-2-yl) -2 -Hydroxy-2-methylbutyramide] -2,4 (1H, 3H) -pyrimidinedione, 6-amino-1- (3-
Chlorophenyl) -3-methyl-5- [4- (3,5,6-trimethyl-
1,4-benzoquinone-2-yl) -2-hydroxy-2-methylbutyramide] -2,4 (1H, 3H) -pyrimidinedione, 6-amino-3-methyl-1- (4-methylphenyl) -5- [4- (3,5,6-trimethyl-1,4-benzoquinone-2-yl) -2-hydroxy-2
-Methylbutyramide] -2,4 (1H, 3H) -pyrimidinedione, 6-amino-1- (4-methoxyphenyl) -3-methyl-5- [4-
(3,5,6-trimethyl-1,4-benzoquinone-2-yl) -2-hydroxy-2-methylbutyramide] -2,4 (1H, 3H) -pyrimidinedione, 3-methyl-6-methyl Amino-1-phenyl
-5- [4- (3,5,6-trimethyl-1,4-benzoquinone-2-yl)
-2-hydroxy-2-methylbutyramide] -2,4 (1H, 3H)-
Pyrimidinedione, 6-dimethylamino-1- (4-fluorophenyl) -3-methyl-5- [4- (3,5,6-trimethyl-1,4-benzoquinone-2-yl) -2-hydroxy- 2-methylbutyramide] -2,4 (1H, 3H) -pyrimidinedione, 6-amino-3-
Methyl-1-phenyl-5-[[4- (3,5,6-trimethyl-1,4-benzoquinone-2-yl) -2-hydroxy-2-methylbutyl]
Amino] -2,4 (1H, 3H) -pyrimidinedione, 6-amino-3
-Methyl-1-phenyl-5- [4- (3,5,6-trimethyl-1,4-
Benzoquinone-2-yl) -2-hydroxy-2-methylbutyl] -2,4 (1H, 3H) -pyrimidinedione, 6-amino-3-methyl-1-phenyl-5- [4- (3,5, 6-trimethyl-1,4-benzoquinone-2-yl) -2-hydroxy-2-methylbutyryl]-
2,4 (1H, 3H) -pyrimidinedione, 6-amino-3-methyl
-1-phenyl-5- [N- [4- (3,5,6-trimethyl-1,4-benzoquinone-2-yl) -2-hydroxy-2-methylbutyl] aminomethyl] -2,4 (1H , 3H) -pyrimidinedione, 6-amino
-3-methyl-1-phenyl-5- [4- (3,5,6-trimethyl-1,4
-Benzoquinone-2-yl) -2-hydroxy-2-methylbutylamidomethyl] -2,4 (1H, 3H) -pyrimidinedione; and the pharmaceutically acceptable salts of the above-listed compounds be able to. Further, pharmacologically acceptable salts include, among these hydroquinone derivatives, those having a functional group capable of forming a salt, sodium salt, potassium salt,
Calcium salt, ammonium salt, hydrochloride, sulfate, acetate, succinate and the like.

The hydroquinone derivative represented by the general formula (I) is obtained by synthesizing a synthetic intermediate corresponding to a 2,4 (1H, 3H) -pyrimidinedione ring constituting the derivative and a synthetic intermediate corresponding to a skeleton of the general formula (II). It can be synthesized by separately synthesizing and then combining both intermediates under appropriate reaction conditions. 2,
6-amino-2,4 (1H, 3H) -pyrimidinedione derivative, which is a synthetic intermediate corresponding to the 4 (1H, 3H) -pyrimidinedione ring, is described in, for example, JP-A-8-109171 (EP-A1- 700908) can be synthesized according to the method described. In addition, among the synthetic intermediates corresponding to the skeleton of the general formula (II),
The synthetic intermediate corresponding to the chroman structure of I) can be prepared, for example, according to the method described in US Pat. No. 4,026,907, and the synthetic intermediate corresponding to the hydroquinone structure of the general formula (IV) or the general formula (IV) Synthetic intermediates corresponding to the quinone structure of V) are described, for example, in the literature (J. Org. Chem., 46 , 2445).
(1981)).

In the general formula (I), -XY- is -N
The compound which is H-CO- is, for example, 6-amino-2,4 (1
The (H, 3H) -pyrimidinedione derivative is nitrosated or nitrated and reduced to give a 5,6-diamino-2,4 (1H, 3H) -pyrimidinedione derivative represented by the general formulas (III) to (V). It can be obtained by dehydration condensation with the corresponding carboxylic acid derivative. The condensation can be carried out by a method commonly used for peptide synthesis and the like, for example, a mixed acid anhydride method, an acid halide method, an activated ester method, a carbodiimide method and the like.

In the general formula (I), -XY- is -N
The compound represented by R ¹⁰ —CH ₂ — is, for example, 5,6-diamino
-2,4 (1H, 3H) -pyrimidinedione derivatives and general formula (III)
It can be synthesized from the aldehyde derivative corresponding to (V) via reductive amination. In addition, the aforementioned-
X-Y- may be reduced to compounds that are -NR ¹⁰ -CO-.

In the general formula (I), -XY- is -C
The compound H ₂ —NR ¹⁰ —CO— can be obtained, for example, from a 6-amino-2,4 (1H, 3H) -pyrimidinedione derivative via Mannich aminomethylation through 6-amino-5- (aminomethyl ) -2,4 (1H, 3H) -pyrimidinedione derivative, which can be obtained by dehydration condensation with carboxylic acid derivatives corresponding to general formulas (III) to (V). The 6-amino-5- (aminomethyl) -2,4 (1H, 3H) -pyrimidinedione derivative is obtained from Sandmeye by a 6-amino-2,4 (1H, 3H) -pyrimidinedione derivative.
It can also be obtained via formylation and reductive amination of r.

In the general formula (I), -XY- is -C
The compound of H ₂ —NR ¹⁰ —CH ₂ — is, for example, a 6-amino-5- (aminomethyl) -2,4 (1H, 3H) -pyrimidinedione derivative and a compound represented by any of the general formulas (III) to (V). It can be synthesized from the corresponding aldehyde derivative via reductive amination. Further, the aforementioned -X-Y- is -CH ₂ -NR ¹⁰ -
The compound which is CO- may be reduced.

In the general formula (I), -XY- is -C
The compound which is H _2- is, for example, 6-amino-2,4 (1H, 3
It can be synthesized from H) -pyrimidinedione derivatives and chloromethyl derivatives corresponding to the general formulas (III) to (V). In the general formula (I), the compound in which —XY— is —CO— is, for example, a 6-amino-2,4 (1H, 3H) -pyrimidinedione derivative and the general formulas (III) to (V) It can be synthesized from the corresponding carboxylic acid derivative via Friedel-Crafts acylation. Further, after the 2,4 (1H, 3H) -pyrimidinedione ring is bonded to one of the skeletons of the general formulas (III) to (V), chroman-type / hydroquinone-type / quinone-type interconversion is performed. Good. These reaction conditions are appropriately selected according to the respective reaction types and types of reactants. In general, the reaction may be selected from conditions generally used in these reactions, and a step of introducing and removing a protecting group may be employed as necessary.

The pharmaceutical composition of the present invention, specifically, a remedy for allergic diseases, can be used in various dosage forms such as external preparations such as ointments and creams, tablets, capsules, powders and other oral preparations, inhalants and injections. Can be used. For example, the hydroquinone derivative of the present invention or a pharmaceutically acceptable salt thereof may be mixed with an ointment base such as petrolatum to form an ointment, and further an additive such as an absorption enhancer may be added. . In addition, the hydroquinone derivative of the present invention or a pharmaceutically acceptable salt thereof is mixed with an excipient such as lactose and starch, a lubricant such as magnesium stearate and talc, and other additives to form a tablet. Can also. The dose of the therapeutic agent for allergic diseases of the present invention is appropriately determined according to the sex, age, weight, type of disease, symptoms, etc. of the patient, and includes, for example, atopic dermatitis, contact dermatitis, psoriasis, etc. Ointment containing 0.01 to 10% of the active ingredient can be applied to the affected area once to several times a day. In addition, the skin disease, bronchial asthma, irritable pneumonia, rejection after organ transplantation,
When applied to graft-versus-host disease, autoimmune diseases, tablets,
Oral preparations such as capsules and powders can be administered orally in single or divided doses in the range of 0.01 to 100 mg / kg per day for adult males.

[0034]

The present invention will be described in more detail with reference to the following examples, but the scope of the present invention is not limited to these examples. (Example 1) 6-amino-5- (6-hydroxy-2,5,7,8-te
Tramethylchroman-2-carboxamide) -3-methyl-1-
Phenyl-2,4 (1H, 3H) -pyrimidinedione 5,6-diamino-3-methyl-1-phenyl-2,4 (1H, 3H) -pyrimidinedione 3.02 g (13 mmol), 6-hydroxy-2 ,Five,
7,8-tetramethylchroman-2-carboxylic acid 3.58 g (1
4.3 mmol), 4- (dimethylamino) pyridine 0.32 g
(2.6 mmol) was suspended in dichloromethane (60 ml) and N, N'-
2.82 g (13.7 mmol) of dicyclohexylcarbodiimide
Was dissolved in 60 ml of dichloromethane and added dropwise at room temperature. After stirring overnight, the mixture was filtered, and the filtrate was concentrated and subjected to silica gel column chromatography to give the title compound (yield 5
7%).

Time-of-flight mass spectrometry (TOF)
-MS): m / z 465 [M + H] ^{+ 1} H-NMR (CDCl ₃ ): δ 1.60 (3H, s), 1.90-2.04 (1H, m),
2.08 (3H, s), 2.18 (3H, s), 2.29 (3H, s), 2.30-2.
38 (1H, m), 2.54-2.64 (2H, m), 3.34 (3H, s), 4.32
(1H, s), 5.17 (2H, bs), 7.27-7.36 (2H, m), 7.53-7.
60 (3H, m), 8.41 (1H, bs)

Example 2 6-amino-5- (6-hydroxy
-2,5,7,8- Tetramethylchroman-2 (R) -carboxami
D) -3-Methyl-1-phenyl-2,4 (1H, 3H) -pyrimidinedi
As a synthetic intermediate having an on chroman ring, with (R)-6-hydroxy-2,5,7,8-tetramethyl chroman-2-carboxylic acid, the title compound was obtained in the same manner as in Example 1 . The ¹ H-NMR of this compound was consistent with the racemic result described in Example 1. [Α] _D + 59 ° (c = 2, CHCl ₃ )

Example 3 6-amino-5- (6-hydroxy)
-2,5,7,8- Tetramethylchroman-2 (S) -carboxami
D) -3-Methyl-1-phenyl-2,4 (1H, 3H) -pyrimidinedi
As a synthetic intermediate having an on chroman ring, (S)-6-hydroxy-2,5,7,8 using tetramethyl chroman-2-carboxylic acid, the title compound was obtained in the same manner as in Example 1 . The ¹ H-NMR of this compound was consistent with the racemic result described in Example 1. [Α] _D -59 ° (c = 2, CHCl ₃ )

Example 4 6-Amino-1- (4-fluorofuran)
Enyl) -5- (6-hydroxy-2,5,7,8-tetramethylchloro
Man-2-carboxamide) -3-methyl-2,4 (1H, 3H) -pyri
Mididinedione 5,6-diamino-1- (4-fluorophenyl) -3-methyl-2,4
The same procedure as in Example 1 was carried out using (1H, 3H) -pyrimidinedione to obtain the title compound. TOF-MS: m / z 483 [M + H] ^{+ 1} H-NMR (CDCl ₃ ): δ 1.60 (3H, s), 1.90-2.05 (1H, m),
2.08 (3H, s), 2.17 (3H, s), 2.28 (3H, s), 2.30-2.
40 (1H, m), 2.54-2.64 (2H, m), 3.35 (3H, s), 4.33
(1H, s), 5.15 (2H, bs), 7.30-7.43 (4H, m), 8.43 (1
H, bs)

Example 5 6-amino-1- (4-chlorophene)
Nyl) -5- (6-hydroxy-2,5,7,8-tetramethylchroma
2-Carboxamide) -3-methyl-2,4 (1H, 3H) -pyrimi
Zindione 5,6-diamino-1- (4-chlorophenyl) -3-methyl-2,4 (1
The title compound was obtained in the same manner as in Example 1 using (H, 3H) -pyrimidinedione. TOF-MS: m / z 499 [M + H] + 1 H-NMR (CDCl 3): δ 1.60 (3H, s),
1.90-2.05 (1H, m), 2.07
(3H, s), 2.18 (3H, s), 2.
29 (3H, s), 2.30-2.40 (1
H, m), 2.55-2.65 (2H, m),
3.34 (3H, s), 4.31 (1H,
s), 5.16 (2H, bs), 7.31
(2H, d, 8.4 Hz), 7.53 (2
H, d, 8.4 Hz), 8.40 (1H,
bs)

Example 6 6-amino-1- (2-chlorofu)
Enyl) -5- (6-hydroxy-2,5,7,8-tetramethylchloro
Man-2-carboxamide) -3-methyl-2,4 (1H, 3H) -pyri
Midinedione 5,6-diamino-1- (2-chlorophenyl) -3-methyl-2,4 (1
The title compound was obtained in the same manner as in Example 1 using (H, 3H) -pyrimidinedione. TOF-MS: m / z 499 [M + H] ^{+ 1} H-NMR (CDCl ₃ ): δ 1.61 (3H, s), 1.90-2.05 (1H, m),
2.09 (3H, s), 2.19 (3H, s), 2.29 (3H, s), 2.30-2.
40 (1H, m), 2.54-2.64 (2H, m), 3.35 (3H, s), 4.30
(1H, s), 5.19 (2H, bs), 7.40-7.55 (3H, m), 7.55-7.
65 (1H, m), 8.40 (1H, bs)

Example 7 6-amino-1- (3-chlorophene)
Nyl) -5- (6-hydroxy-2,5,7,8-tetramethylchroma
2-Carboxamide) -3-methyl-2,4 (1H, 3H) -pyrimi
Zindione 5,6-diamino-1- (3-chlorophenyl) -3-methyl-2,4 (1
The title compound was obtained in the same manner as in Example 1 using (H, 3H) -pyrimidinedione. TOF-MS: m / z 499 [M + H] ^{+ 1} H-NMR (CDCl ₃ ): δ 1.60 (3H, s), 1.90-2.04 (1H, m),
2.08 (3H, s), 2.18 (3H, s), 2.29 (3H, s), 2.30-2.
38 (1H, m), 2.54-2.64 (2H, m), 3.34 (3H, s), 4.32
(1H, s), 5.17 (2H, bs), 7.38-7.65 (4H, m), 8.43 (1
H, bs)

Example 8 6-amino-5- (6-hydroxy
-2,5,7,8-Tetramethylchroman-2-carboxamide)-
3-methyl-1- (4-methylphenyl) -2,4 (1H, 3H) -pirimi
Zindione 5,6-diamino-3-methyl-1- (4-methylphenyl) -2,4 (1
The title compound was obtained in the same manner as in Example 1 using (H, 3H) -pyrimidinedione. TOF-MS: m / z 479 [M + H] ^{+ 1} H-NMR (CDCl ₃ ): δ 1.60 (3H, s), 1.90-2.04 (1H, m),
2.08 (3H, s), 2.18 (3H, s), 2.29 (3H, s), 2.30-2.
38 (1H, m), 2.39 (3H, s), 2.54-2.64 (2H, m), 3.34
(3H, s), 4.33 (1H, s), 5.18 (2H, bs), 7.20 (2H, d,
8.5 Hz), 7.34 (2H, d, 8.5 Hz), 8.40 (1H, bs)

Example 9 6-amino-5- (6-hydroxy
-2,5,7,8-Tetramethylchroman-2-carboxamide)-
1- (4-methoxyphenyl) -3-methyl-2,4 (1H, 3H) -pyri
Mididinedione 5,6-diamino-1- (4-methoxyphenyl) -3-methyl-2,4
The same procedure as in Example 1 was carried out using (1H, 3H) -pyrimidinedione to obtain the title compound. TOF-MS: m / z 495 [M + H] ^{+ 1} H-NMR (CDCl ₃ ): δ 1.60 (3H, s), 1.90-2.05 (1H, m),
2.10 (3H, s), 2.19 (3H, s), 2.29 (3H, s), 2.30-2.
40 (1H, m), 2.55-2.65 (2H, m), 3.35 (3H, s), 3.87
(3H, s), 4.34 (1H, s), 5.16 (2H, bs), 7.06 (2H, d,
9.0 Hz), 7.25 (2H, d, 9.0 Hz), 8.40 (1H, bs)

Example 10 6-amino-5- (6-hydroxy
C-2,5,7,8-Tetramethylchroman-2-carboxami
D) -1-Phenyl-3-propyl-2,4 (1H, 3H) -pyrimidine
Dione 5,6-diamino-1-phenyl-3-propyl -2,4 (1H, 3H) -
The title compound was obtained in the same manner as in Example 1 using pyrimidinedione. TOF-MS: m / z 493 [M + H] ^{+ 1} H-NMR (CDCl ₃ ): δ 0.85 (3H, t, 7.2 Hz), 1.48-1.58
(m, 2H), 1.60 (3H, s), 1.90-2.04 (1H, m), 2.08 (3H,
s), 2.18 (3H, s), 2.29 (3H, s), 2.30-2.38 (1H, m),
2.54-2.64 (2H, m), 3.69-3.75 (2H, m), 4.32 (1H,
s), 5.17 (2H, bs), 7.27-7.36 (2H, m), 7.53-7.60 (3
H, m), 8.4 (1H, b)

Example 11 5- (6-hydroxy-2,5,
7,8-tetramethylchroman-2-carboxamide) -3-me
Tyl-6-methylamino-1-phenyl-2,4 (1H, 3H) -pyri
Mididione 5-amino-3-methyl-6-methylamino-1-phenyl-2,4
The same procedure as in Example 1 was carried out using (1H, 3H) -pyrimidinedione to obtain the title compound. TOF-MS: m / z 479 [M + H] ^{+ 1} H-NMR (DMSO-d ₆ ): δ 1.46 (3H, s), 1.74-1.88 (1H,
m), 2.00 (3H, s), 2.07 (3H, s), 2.12 (3H, s), 2.20-
2.30 (1H, m), 2.55-2.65 (5H, m), 3.15 (3H, s), 7.2
5-7.35 (2H, m), 7.48-7.56 (3H, m), 8.5 (1H, b)

Example 12 1- (4-Fluorophenyl )
) -6-dimethylamino-5- (6-hydroxy-2,5,7,8-tetra
(Lamethylchroman-2-carboxamide) -3-methyl-2,4
(1H, 3H) -pyrimidinedione 5-amino-6-dimethylamino-1- (4-fluorophenyl)-
The title compound was obtained in the same manner as in Example 1 using 3-methyl-2,4 (1H, 3H) -pyrimidinedione. TOF-MS: m / z 511 [M + H] ^{+ 1} H-NMR (DMSO-d ₆ ): δ 1.47 (3H, s), 1.75-1.90 (1H,
m), 2.01 (3H, s), 2.08 (3H, s), 2.12 (3H, s), 2.20-
2.30 (1H, m), 2.37 (6H, s), 2.54-2.64 (2H, m), 3.1
9 (3H, s), 7.30-7.43 (4H, m), 8.5 (1H, b)

Example 13 6-amino-5- (6-methoxy)
-2,5,7,8-Tetramethylchroman-2-carboxamide)-
Using 3-methyl-1-phenyl-2,4 (1H, 3H) -pyrimidinedione 6-methoxy -2,5,7,8 -tetramethylchroman-2-carboxylic acid, by the same operation as in Example 1. The title compound was obtained. TOF-MS: m / z 479 [M + H] ^{+ 1} H-NMR (CDCl ₃ ): δ 1.61 (3H, s), 1.90-2.04 (1H, m),
2.12 (3H, s), 2.21 (3H, s), 2.28 (3H, s), 2.30-2.
38 (1H, m), 2.50-2.70 (2H, m), 3.35 (3H, s), 3.62
(3H, s), 5.18 (2H, bs), 7.27-7.36 (2H, m), 7.52-7.
60 (3H, m), 8.42 (1H, bs)

Example 14 5- (6-acetoxy-2,5,
7,8-tetramethylchroman-2-carboxamide) -6-a
Mino-3-methyl-1-phenyl-2,4 (1H, 3H) -pyrimidine
Compounds of dione Example 1 1.77 g (3.80 mmol) and pyridine 0.1
54 ml (1.90 mmol) was dissolved in 30 ml of dichloromethane, 0.714 ml (7.60 mmol) of acetic anhydride was added dropwise under ice cooling, and the mixture was stirred at room temperature overnight. The reaction solution was washed sequentially with 1 N hydrochloric acid and 10% brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was dispersed in ethyl acetate, and filtered to give the title compound (87% yield). TOF-MS: m / z 507 [M + H] + 1 H-NMR (CDCl 3): δ 1. 65 (3H, s), 1.90-2.04 (1H,
m), 1.93 (3H, s), 2.04 (3H, s), 2.28 (6H, s), 2.30
-2.45 (1H, m), 2.50-2.70 (2H, m), 3.35 (3H, s), 4.
69 (1H, b), 5.30 (1H, b), 7.26-7.35 (2H, m), 7.52-
7.60 (3H, m), 7.89 (0.5H, b), 8.40 (0.5H, b)

Example 15 6-amino-3-methyl-1-
Phenyl-5- [4- (3,5,6-trimethyl-1,4-benzoquinone
-2-yl) -2-hydroxy-2-methylbutyramide] -2,4
(1H, 3H) -pyrimidinedione obtained by oxidizing 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid with cerium (IV) ammonium nitrate
4- (3,5,6-trimethyl-1,4-benzoquinone-2-yl) -2-
The title compound (62% yield) was obtained in the same manner as in Example 1 using hydroxy-2-methylbutyric acid. One of the metabolites in plasma when the compound of Example 1 was orally administered to guinea pigs was the present compound. TOF-MS: m / z 481 [M + H] ^{+ 1} H-NMR (CDCl ₃ ): δ 1.54 (3H, s), 1.63-1.75 (1H, m),
1.95-2.05 (1H, m), 1.97 (3H, s), 1.99 (3H, s), 2.
01 (3H, s), 2.41-2.52 (1H, m), 2.63-2.73 (1H, m),
3.36 (3H, s), 4.11 (1H, s), 5.33 (2H, bs), 7.37-7.
40 (2H, m), 7.52-7.63 (3H, m), 8.54 (1H, bs)

Example 16 6-amino-5- [4- (2,5-di
(Hydroxy-3,4,6-trimethylphenyl) -2-hydroxy
-2-methylbutyramide] -3-methyl-1-phenyl-2,4
(1H, 3H) -pyrimidinedione 0.48 g (1.0 mmol) of the compound of Example 15 was added to ethanol 3
The mixture was dissolved in ml, and stirred at room temperature overnight in a hydrogen atmosphere in the presence of 10% Pd / C. The catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure to obtain the title compound. Electrospray mass spectrometry (ESI-MS): m / z 483.21
[M + H] ⁺

Example 17 6-Amino-5-[(6-hydro
(Xy-2,5,7,8-tetramethyl-2-chromanylmethyl)
Mino] -3-methyl-1-phenyl-2,4 (1H, 3H) -pyrimidine
Dione 464 mg (1.0 mmol) of the compound of Example 1 was dissolved in 10 ml of THF, and 0.24 ml of borane-methylsulfide complex (10 M,
2.4 mmol) and refluxed for 5 hours. The reaction solution was ice-cooled, 1N hydrochloric acid (2.4 ml) was added, and the mixture was further refluxed for 2 hours. The reaction solution was concentrated under reduced pressure, 1N aqueous sodium hydroxide solution was added, and the mixture was extracted with dichloromethane. The organic layer was washed with 10% brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was crystallized by adding ethyl acetate and ether.
The title compound (35% yield) was obtained. TOF-MS: m / z 451 [M + H] ^{+ 1} H-NMR (CDCl ₃ ): δ 1.24 (3H, s), 1.65-1.80 (1H, m),
2.05 (3H, s), 2.10 (3H, s), 2.12 (3H, s), 1.95-2.
20 (1H, m), 2.60-2.70 (2H, m), 3.02 (2H, bs), 3.36
(3H, s), 4.24 (1H, s), 4.78 (2H, bs), 7.25-7.35
(2H, m), 7.50-7.60 (3H, m)

Example 18 6-amino-5- [N- (6-hydrido)
Roxy-2,5,7,8-tetramethyl-2-chromanylmethyl)
Aminomethyl] -3-methyl-1-phenyl-2,4 (1H, 3H) -pi
Limidindione 6-amino-3-methyl-1-phenyl-2,4 (1H, 3H) -pyrimidinedione 5.00 g (23 mmol) in dimethylformamide
Suspend in 77 ml and add 2.57 ml of phosphorus oxychloride (27.6 mmo
l) was added and reacted at 60 ° C. for 3 hours. The reaction solution was diluted with water, adjusted to pH about 12 with sodium hydroxide, and the precipitate was collected by filtration. This crude product is ethanol / ethyl acetate /
Recrystallization in a mixture of water gave aldehyde: 6-amino-5-formyl-3-methyl-1-phenyl-2,4 (1H, 3H) -pyrimidinedione (yield 75%).

On the other hand, 1.0 g (4.0 mmol) of 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide was added to THF.
Dissolve the borane-methyl sulfide complex in 1.9 ml.
ml (10 M, 19 mmol) was added, and the mixture was refluxed for 7 hours. The reaction solution was ice-cooled, 9.6 ml of 1N hydrochloric acid was added, and the mixture was further refluxed for 2 hours. The reaction solution was concentrated under reduced pressure, 1N aqueous sodium hydroxide solution was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with 10% brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography to give amine: 2-aminomethyl-6-hydroxy-2,5,7, 8-
Tetramethylchroman (55% yield) was obtained.

204 mg of the aldehyde thus prepared
(0.83 mmol) and 353 mg (1.25 mmol) of amine were dissolved in 4 ml of dichloroethane and reacted at 70 ° C. for 7 hours. After cooling to room temperature, sodium triacetoxyborohydride
352 mg (1.66 mmol) was added and reacted at room temperature overnight.
After adding dilute hydrochloric acid to the reaction solution, adjust pH 8-9 with sodium hydroxide.
And extracted with dichloromethane. The organic layer was washed with 10% brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and crystallized from ethyl acetate / ethanol to give the title compound (26% yield). TOF-MS: m / z 466 [M + H] ^{+ 1} H-NMR (DMSO-d ₆ ): δ 1.09 (3H, s), 1.40-1.60 (1H,
m), 1.99 (3H, s), 2.03 (3H, s), 2.07 (3H, s), 1.85-
2.15 (1H, m), 2.50-2.80 (4H, m), 3.12 (3H, s), 3.5
6 (1H, d, 12 Hz), 3.75 (1H, d, 12 Hz), 5.40 (2H, b
s), 7.10-7.26 (2H, m), 7.40-7.55 (3H, m)

Example 19 6-amino-5- (N-butyl-6)
-Hydroxy-2,5,7,8-tetramethylchroman-2-cal
Boxamidomethyl) -3-methyl-1-phenyl-2,4 (1H, 3
H) -Pyrimidinedione 6-amino-5-formyl-3-methyl-1 according to Example 18.
-Reductive amination of phenyl-2,4 (1H, 3H) -pyrimidinedione and butylamine via 6-amino-5- (N-butylaminomethyl) -3-methyl-1-phenyl-2,4 (1H, 3H ) -Pyrimidinedione was prepared. This intermediate and 6-hydroxy-2,
5,7,8-Tetramethylchroman-2-carboxylic acid was condensed by a conventional method to obtain the title compound (36% yield). ¹ H-NMR (CDCl ₃ ): δ 0.95 (3H, t, 7.2 Hz), 1.33 (2H,
t of q, 7.2 Hz, 7.2 Hz), 1.57 (3H, s), 1.60-1.75
(3H, m), 2.03 (3H, s), 2.15 (3H, s), 2.17 (3H, s),
2.45-2.68 (3H, m), 2.45-2.65 (2H, m), 3.32 (3H,
s), 3.52-3.67 (1H, m), 3.80-3.95 (1H, m), 4.28 (1H, m
bs), 4.41 (1H, d, 16 Hz), 4.52 (1H, d, 16 Hz), 5.8
5 (b), 7.13-7.32 (2H, m), 7.48-7.60 (3H, m)

(Evaluation Example 1) Suppression of picryl chloride-induced dermatitis
To verify the dermatitis inhibition hydroquinone derivative of the present invention for producing a typical type IV allergic model effective the Asherson's method for picryl chloride-induced dermatitis inflammation (Immunology, 15, 405 (1968 ) ).
Sensitization was induced by applying 0.1 ml of a 7% (w / v) picryl chloride / acetone solution to the abdominal skin of male ICR mice.
On day 7 of sensitization, 1% (w / v) picryl chloride / acetone solution
Allergic reaction was induced by applying 0.02 ml to the auricle, and immediately thereafter, 0.04 ml of acetone (control) or a 0.25 to 2.5% (w / v) test compound / acetone solution was applied to the auricle. Trigger 2
After 4 hours, the thickness of the pinna was measured, and the inhibitory effect of the test compound on dermatitis was evaluated using the difference from the pinna thickness before the induction as an index.

As a result, as shown in Table 1, it was confirmed that the hydroquinone derivatives of the present invention exhibited the indicated inhibition rates when applied with the acetone solutions having the respective indicated concentrations, and exhibited a swelling inhibitory action. Was done. That is, it was confirmed that when used as an external preparation, the hydroquinone derivative of the present invention was absorbed from the skin and exhibited an inhibitory effect when placed on the affected part of dermatitis.

[0058]

[Table 1]

(Evaluation Example 2) Inhibition of albumin-induced asthma
In order to verify the inhibitory effect of the hydroquinone derivative of the present invention on asthma, the inhibitory effect upon oral administration was evaluated using albumin-induced asthma as a model. Hartley male guinea pigs were treated with 1% ovalbumin at 10 minutes / day for 8 consecutive days.
Inhalation was performed using an ultrasonic nebulizer to induce sensitization. One week after the final sensitization, 2% ovalbumin was inhaled for 5 minutes to induce an allergic reaction. Intravenous administration of 10 mg / kg of metyrapone 24 hours and 1 hour before induction, propylene glycol 1 hour before and 3 hours after induction
(Control) Or a test substance / propylene glycol solution was orally administered, and pyrilamine 10 mg / kg was intraperitoneally administered 30 minutes before the induction. 1 minute after induction, 4, 5, 6, 7 and 8 hours later, doub
Airway resistance was measured by the le flow plethysmograph method, and the asthma suppressing effect of the test compound was evaluated.

As a result, the compound of Example 1 (dose of 100 mg)
/ kg) shows a 62% inhibition rate against the airway reaction 1 minute after the induction, and 50% against the airway response (AUC) 4 to 8 hours after the induction.
Showed the suppression rate. That is, when used as an oral administration agent,
It was confirmed that the hydroquinone derivative of the present invention was absorbed from the gastrointestinal tract and exerted an inhibitory effect on the airway reaction of asthma.

(Formulation Example 1) Water-soluble ointment A water-soluble ointment having the following composition was prepared by a conventional method. Ingredient (content per 2 g of ointment) Compound of Example 1 40 mg Polyethylene glycol 400 1372 mg Polyethylene glycol 4000 588 mg

[0062] The (Formulation Example 2) in taking tablets conventional manner to create oral tablets having the following composition. Ingredient (content per tablet) Compound of Example 1 100 mg Lactose 353 mg Carboxymethylcellulose calcium 30 mg Hydroxypropylcellulose 7 mg Magnesium stearate 5 mg Crystalline cellulose 5 mg

[0063]

EFFECT OF THE INVENTION The hydroquinone derivative of the present invention is effective against allergic inflammation,
It has a remarkable anti-inflammatory effect. Since the hydroquinone derivative of the present invention effectively suppresses type IV allergic inflammation, it is useful as a therapeutic drug for allergic diseases, particularly, type IV allergic diseases. In addition, since it is absorbed from the skin when administered as an external preparation, it is useful for treating skin diseases such as atopic dermatitis, contact dermatitis and psoriasis. Furthermore, since it is absorbed from the digestive tract by oral administration, in addition to the above-mentioned extensive skin diseases, it is used for the treatment of bronchial asthma, irritable pneumonia, rejection after organ transplantation, graft-versus-host disease, autoimmune disease, etc. Is also useful. Further, since the hydroquinone derivative is a non-steroidal substance, it has an advantage of not exhibiting steroid-like side effects.

──────────────────────────────────────────────────の Continued on the front page (51) Int.Cl. ⁶ Identification code FI A61K 31/505 ADA A61K 31/505 ADA C07D 405/06 239 C07D 405/06 239 405/12 239 405/12 239 (72) Invention Osamu Takahashi 3-17-35 Niisominami, Toda City, Saitama Prefecture Inside Japan Energy Co., Ltd.

Claims (7)

[Claims] 1. A compound of the general formula (I): (Wherein, R ¹ represents a phenyl group, and the phenyl group is a halogen atom, an alkyl group having 1 to 4 carbon atoms, or a
R ² may represent a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, and R ³ and R ⁴
Independently represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, R ⁵ represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, and R ⁶ , R ⁷ and R ⁸ independently represent a hydrogen atom Or represents an alkyl group having 1 to 4 carbon atoms; P represents a hydroxyl group;
Is a hydroxyl group, an alkoxy group having 1 to 4 carbon atoms,
Represents an acyloxy group or an oxo group of 18, wherein P and Q are
R may represent a hydroxyl group, an alkoxy group having 1 to 4 carbon atoms, an acyloxy group or an oxo group having 1 to 18 carbon atoms, provided that one of the Q and R is When an oxo group, the other is also an oxo group, and X represents a single bond, a —NR ¹⁰ — group or a —CH ₂ —NR ¹⁰ — group,
Here, R ¹⁰ represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, Y represents a methylene group or a carbonyl group,
The dotted line attached to the 6-membered ring indicates that the ring has the most double bonds. Or a pharmaceutically acceptable salt thereof. 2. The compound according to claim 1, wherein in formula (I), P and Q together form an ether bond. 3. In the general formula (I), P represents a hydroxyl group, Q represents a hydroxyl group, an alkoxy group having 1 to 4 carbon atoms or an acyloxy group having 1 to 18 carbon atoms, and R represents a hydroxyl group and 1 carbon atom. The compound according to claim 1, which represents an alkoxy group having 1 to 4 carbon atoms or an acyloxy group having 1 to 18 carbon atoms. 4. The compound according to claim 1, wherein in the general formula (I), P represents a hydroxyl group, and Q and R both represent an oxo group. (5) 6-amino-5- (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide) -3-methyl-1-
Phenyl-2,4 (1H, 3H) -pyrimidinedione or a pharmaceutically acceptable salt thereof. 6. A pharmaceutical composition comprising the compound according to any one of claims 1 to 5 as an active ingredient. 7. A remedy for allergic diseases comprising the compound according to any one of claims 1 to 5 as an active ingredient.